-
-
-
-
-
-
-
Gilead and Lakefront complete $1.675 billion Ouro Medicines acquisition
-
-
-
-
-
-
-
Gilead Sciences completes $7.8 billion Arcellx acquisition
-
-
-
-
-
-
-
BMO Capital Reiterates Outperform Rating on Gilead Sciences (GILD)
-
-
-
-
-
-
-
Galapagos enters partnership with Gilead for autoimmune drug development
-
-
-
-
-
-
-
Gilead HIV drug combination maintains viral suppression in phase 3 trials
-
-
-
-
-
-
-
Gilead to acquire Arcellx for $7.8 billion to gain control of cancer therapy
-
-
-
-
-
-
-
Gilead HIV drug combination meets primary goal in phase 3 trial
-
1,180,476 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

